The Irreversible FGFR Inhibitor KIN-3248 Overcomes FGFR2 Kinase Domain Mutations.

Eranga Roshan Balasooriya Qibiao Wu Haley Ellis Yuanli Zhen Bryanna L Norden Ryan B Corcoran Adithi Mohan Eric Martin Aleksandra Franovic John S Tyhonas Matthew Lardy Kathryn B Grandinetti Robert Pelham Liliana Soroceanu Vanessa Silva Silveira Nabeel El-Bardeesy

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

Thus, KIN-3248 is a novel FGFR1-4 inhibitor whose distinct activity profile against FGFR kinase domain mutations highlights its potential for the treatment of ICC and other FGFR-driven cancers.

Keyphrases

tyrosine kinase
protein kinase
young adults